HealthcareServices

Global Crohn’s Disease (CD) Treatment Market Set for Strong Expansion, Reaching $16 Billion With 5.6% CAGR by 2030

February 23, 2026February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the crohn’s disease (cd) treatment market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Crohn’s Disease (CD) Treatment Market covering 2026–2035?

The crohn’s disease (cd) treatment market size has exhibited consistent growth over recent years. It is forecast to increase from $12.32 billion in 2025 to $12.88 billion in 2026, at a compound annual growth rate (CAGR) of 4.5%. The expansion witnessed in prior periods can be attributed to factors such as the increasing prevalence of inflammatory bowel disease, the limitations of traditional corticosteroids, disease management focused on hospitals, delayed diagnosis rates, and a reliance on immunomodulators.

The crohn’s disease (CD) treatment market is projected to experience robust expansion over the coming years, anticipated to reach $16.01 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.6%. This expansion over the forecast period stems from progress in biologics development, the rise of precision medicine, enhanced patient understanding, refined diagnostic procedures, and greater access to specialized gastroenterology care. Significant developments anticipated in the forecast period encompass an increasing adoption of biologic treatments, the proliferation of targeted small molecule medications, a stronger emphasis on achieving lasting disease remission, the evolution of personalized therapeutic strategies, and the incorporation of multi-drug regimens.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12902&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Crohn’s Disease (CD) Treatment Market?

The Crohn’s disease (CD) treatment market is anticipated to expand due to the rising incidence of inflammatory bowel diseases. Inflammatory bowel disease (IBD) encompasses a range of chronic inflammatory conditions primarily impacting the gastrointestinal (GI) tract. Treatment for Crohn’s disease (CD) alleviates symptoms, diminishes inflammation, encourages remission, and improves the overall quality of life for those afflicted with this chronic inflammatory bowel condition. For example, data from September 2023 by the United States National Library of Medicine, a US-based medical library, indicated that in Canada, the estimated incidence of inflammatory bowel diseases (IBD) was 30 per 100,000 person years in 2023, with an expected annual increase of about 0.58%. Furthermore, as of 2023, IBD prevalence in Canada stood at approximately 825 per 100,000, with predictions suggesting a potential rise to 1.1% of the population by 2035. Consequently, the growing occurrence of inflammatory bowel diseases is a significant driver for the Crohn’s disease (CD) treatment market.

What Leading Segments Are Studied In The Crohn’s Disease (CD) Treatment Market?

The crohn’s disease (cd) treatment market covered in this report is segmented –

1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Antibiotics: Metronidazole, Ciprofloxacin, Rifaximin

2) By Amino Salicylates: Mesalamine, Sulfasalazine

3) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

4) By Immunomodulators: Azathioprine, Mercaptopurine, Methotrexate

5) By Other Drug Types: Biologic Therapies, Janus Kinase Inhibitors, Small Molecules

Which Trends Are Guiding The Evolution Of The Crohn’s Disease (CD) Treatment Market?

Leading firms within the Crohn’s disease (CD) treatment market are concentrating on creating sophisticated technologies, specifically non-invasive diagnostic platforms reliant on biomarkers. This effort aims to refine disease identification, elevate the precision of monitoring, and facilitate customized therapeutic choices. These non-invasive diagnostic innovations for Crohn’s disease involve instruments capable of analyzing biological samples without the need for intrusive methods. Their purpose is to allow for quicker detection of inflammation, more effective tracking of disease progression, and an enhanced experience for patients. An illustrative example occurred in March 2023, when The IRR Chemistry Hub, an interdisciplinary research facility located in Scotland, introduced IBDSENSE. This fluorescence-based technology was designed to augment the diagnosis and ongoing surveillance of inflammatory bowel disease, which encompasses Crohn’s disease. The system operates by quantifying the enzymatic activity of Granzyme B (GzmB) within patient biosamples. This provides a convenient, non-invasive approach for evaluating the course of the disease and guiding treatment decisions.

Which Leading Companies Dominate The Crohn’s Disease (CD) Treatment Market Share?

Major companies operating in the crohn’s disease (cd) treatment market are AbbVie Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Amneal Pharmaceuticals LLC, Ferring B.V., Eli Lilly and Company, Sanofi S.A., Bristol-Myers Squibb Company, Galapagos NV, Abivax, Biogen Inc., Gilead Sciences, RedHill Biopharma, Prometheus Biosciences, Hoffmann-La Roche

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report

How Does The Crohn’s Disease (CD) Treatment Market Perform Across Major Global Regions?

North America was the largest region in the Crohn’s disease (CD) treatment market in 2025. The regions covered in the crohn’s disease (cd) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Crohn’s Disease (CD) Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12902&type=smp

Browse Through More Reports Similar to the Global Crohn’s Disease (CD) Treatment Market 2026, By The Business Research Company

Rare Inflammatory Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Crohns Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report

Inflammatory Bowel Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795